NOMINATION OF THOMAS SPITZ AS CHIEF EXECUTIVE OFFICER
NOMINATION OF THOMAS SPITZ AS CHIEF EXECUTIVE OFFICER
Amsterdam, the Netherlands – Flow Traders Ltd. (Euronext: FLOW) announces the nomination of Thomas Spitz as Chief Executive Officer and Executive Director of the Board.
Thomas Spitz will join Flow Traders on 1 September 2025 and is nominated as Chief Executive Officer and Executive Director of the Board, subject to regulatory and shareholder approval. In his role as Chief Executive Officer, Thomas will be responsible for executing Flow Traders' strategic agenda, which includes the Company's growth and diversification strategy and Trading Capital Expansion Plan.
Mr. Spitz is a distinguished senior financial markets executive with over two decades of experience building and leading world-class trading operations across markets globally. He possesses both the technical knowledge and the innovation mindset needed to further drive Flow Traders' strategic agenda. Mr. Spitz has a proven track record of leading trading, sales and research organizations, managing diverse international teams, and driving significant growth. His expertise extends to managing stakeholder relationships across all layers of an organization and building strategic partnerships.
Prior to joining Flow Traders, Mr. Spitz was the CEO of QuantCube Middle East, a technology firm specializing in alternative data and analytics. He also served as Head of Global Markets at First Abu Dhabi Bank from 2022 to 2024. Before that, Thomas spent more than 20 years at Crédit Agricole, in several leadership roles across all asset classes. He last held the role of Head of Global Markets Trading, FICC & EQD. Thomas comes with long-standing international experience, having managed teams in over 15 countries.
The Board of Flow Traders has nominated Mr. Spitz for election as Executive Director of the Board at a Special General Meeting of shareholders scheduled to take place later this year. The convening notice, agenda and other documentation relating to the meeting will be published in due course.
Rudolf Ferscha, Chairman of the Board, commented:
'We are pleased that Thomas is joining Flow Traders as Chief Executive Officer and Executive Director of the Board. He brings a wealth of experience leading trading, sales and research organizations at global financial institutions while driving growth through innovative business strategies. We are confident that he will excel at executing our strategic agenda and lead Flow Traders into its next phase of growth.
On behalf of the entire Board I would also like to thank Mike Kuehnel, whose term has been extended to 31 August, for his leadership at Flow Traders over the past four years and for supporting and assisting the Board throughout the additional transition period since our AGM in June. This allows for a seamless transition, both at the CEO and Board level. We wish Mike every success in all his future endeavors'
Thomas Spitz, added:
'I am honored and excited to be nominated as the next CEO of Flow Traders. I see tremendous opportunities given the extraordinary capabilities the Company has built over the past two decades. I look forward to meeting the team and together expand our market leadership, drive our strategic growth agenda, and provide exceptional value to all of our stakeholders.'
Contact Details
Flow Traders Ltd.
Investors / Media Eric PanPhone: +31 20 7996799
Email: [email protected]
About Flow Traders
Flow Traders is a leading trading firm providing liquidity in multiple asset classes, covering all major exchanges. Founded in 2004, Flow Traders is a leading global ETP market maker and has leveraged its expertise in trading European equity ETPs to expand into fixed income, commodities, digital assets and FX globally. Flow Traders' role in financial markets is to ensure the availability of liquidity and enabling investors to continue to buy or sell financial instruments under all market circumstances, thereby ensuring markets remain resilient and continue to function in an orderly manner. In addition to its trading activities, Flow Traders has established a strategic investment unit focused on fostering market innovation and aligned with our mission to bring greater transparency and efficiency to the financial ecosystem. With over two decades of experience, we have built a team of over 600 talented professionals, located globally, contributing to the firm's entrepreneurial culture and delivering the company's mission.
Important Legal Information
This press release is prepared by Flow Traders Ltd. and is for information purposes only. It is not a recommendation to engage in investment activities and you must not rely on the content of this document when making any investment decisions. The information in this document does not constitute legal, tax, or investment advice and is not to be regarded as investor marketing or marketing of any security or financial instrument, or as an offer to buy or sell, or as a solicitation of any offer to buy or sell, securities or financial instruments.
The information and materials contained in this press release are provided 'as is' and Flow Traders Ltd. or any of its affiliates ('Flow Traders') do not warrant the accuracy, adequacy or completeness of the information and materials and expressly disclaim liability for any errors or omissions. This press release is not intended to be, and shall not constitute in any way a binding or legal agreement, or impose any legal obligation on Flow Traders. All intellectual property rights, including trademarks, are those of their respective owners. All rights reserved. All proprietary rights and interest in or connected with this publication shall vest in Flow Traders. No part of it may be redistributed or reproduced without the prior written permission of Flow Traders.
This press release may include forward-looking statements, which are based on Flow Traders' current expectations and projections about future events, and are not guarantees of future performance. Forward looking statements are statements that are not historical facts, including statements about our beliefs and expectations. Words such as 'may', 'will', 'would', 'should', 'expect', 'intend', 'estimate', 'anticipate', 'project', 'believe', 'could', 'hope', 'seek', 'plan', 'foresee', 'aim', 'objective', 'potential', 'goal' 'strategy', 'target', 'continue' and similar expressions or their negatives are used to identify these forward-looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of Flow Traders. Such factors may cause actual results, performance or developments to differ materially from those expressed or implied by such forward-looking statements. Accordingly, no undue reliance should be placed on any forward-looking statements. Forward-looking statements speak only as at the date at which they are made. Flow Traders expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statements contained in this press release to reflect any change in its expectations or any change in events, conditions or circumstances on which such statements are based unless required to do so by applicable law.
Financial objectives are internal objectives of Flow Traders to measure its operational performance and should not be read as indicating that Flow Traders is targeting such metrics for any particular fiscal year. Flow Traders' ability to achieve these financial objectives is inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond Flow Traders' control, and upon assumptions with respect to future business decisions that are subject to change. As a result, Flow Traders' actual results may vary from these financial objectives, and those variations may be material.
Efficiencies are net, before tax and on a run-rate basis, i.e. taking into account the full-year impact of any measure to be undertaken before the end of the period mentioned. The expected operating efficiencies and cost savings were prepared on the basis of a number of assumptions, projections and estimates, many of which depend on factors that are beyond Flow Traders' control. These assumptions, projections and estimates are inherently subject to significant uncertainties and actual results may differ, perhaps materially, from those projected. Flow Traders cannot provide any assurance that these assumptions are correct and that these projections and estimates will reflect Flow Traders' actual results of operations.
By accepting this document you agree to the terms set out above. If you do not agree with the terms set out above please notify [email protected] immediately and delete or destroy this document.
Market Abuse Regulation
This press release contains information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Attachment Project Blue II press release
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Euronext CEO Says US Starting to Resemble ‘Emerging Market'
By and Merryn Somerset Webb Save Subscribe to Merryn Talks Money on Apple Podcasts Subscribe to Merryn Talks Money on Spotify There's a growing sense among global investors that it might be time to look east. As in, toward Europe and away from an increasingly unstable America that, at least on the equity side says Euronext CEO Stéphane Boujnah, is beginning to resemble an 'emerging market.'
Business Wire
2 hours ago
- Business Wire
Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) (the 'Company'), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Stephen From as Chief Executive Officer and a member of the Company's Board of Directors (the 'Board'), effective August 7, 2025. Adam Sachs, current Chief Executive Officer, Co-Founder, and a member of the Board, will remain with the Company as President, Co-Founder, and a member of the Board in an operational capacity as a member of the Company's leadership team. Mr. From brings over 20 years of leadership in the healthcare and financial industry. He most recently served as CEO of Aruna Bio, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and CEO, and from February 2021 through January 2022 served as Executive Chairman of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space. Before EyeGate, Mr. From was CFO of Centelion SAS, then a biotech subsidiary of Sanofi‑Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University 'I am honored to join the Vicarious Surgical team at this pivotal time in its evolution. The Company's technology offers a significant advancement from today's surgical approaches with the potential to transform modern surgery and improve outcomes for patients worldwide,' said Mr. From. 'I look forward to working alongside this talented team and Board to advance our strategic priorities and deliver on the promise of this innovative platform.' 'It has been an incredible journey to lead Vicarious Surgical from its inception through pre-clinical testing, and I'm proud of all we've accomplished to date. As I transition into the role of President, I'm excited to welcome Stephen as our new CEO,' said Adam Sachs, current Chief Executive Officer, Co-Founder, and Board member. 'I believe his leadership and experience are exactly what we need at this pivotal stage, and I look forward to working closely with him to advance our mission of transforming surgical care through innovative robotics.' In connection with the appointment of Mr. From, the Company is also announcing, as required by New York Stock Exchange Listed Company Manual Rule 303A.08 (the 'Inducement Rule'), a stock option award to be made to Mr. From as a material inducement to his entering into employment with the Company. The stock option award was approved by the Company's Board and by its Compensation Committee with a grant date of August 7, 2025. The stock option to be granted to Mr. From will be exercisable for up to 297,600 shares of the Company's Class A common stock, will have an exercise price equal to the closing price of the Class A common stock on the date of grant, and will expire on the ten-year anniversary of the grant date. One-quarter of the stock options will vest and become exercisable on the one-year anniversary of the grant date, and the remainder of the stock options will vest in thirty-six equal consecutive, equal monthly installments thereafter, subject to Mr. From's continued service to the Company through each vesting date and subject to accelerated vesting in certain circumstances. The stock option award will be made outside of the Company's existing 2021 Equity Incentive Plan, as amended (the 'Plan'), but will be subject to terms and conditions generally consistent with those in the Plan, other than with respect to such terms and conditions intended to comply with the Inducement Rule. About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the potential for the Company's technology to improve patient outcomes, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company's Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of the Company's initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product and service development activities; the potential attributes and benefits of the Company's product candidates and services; the Company's ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing license, manufacture, supply and distribution agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company's business, financial condition and results of operations; the Company's intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company's filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Hamilton Spectator
6 hours ago
- Hamilton Spectator
Rubicon Organics Announces the Results of the Annual General and Special Meeting, Appoints Chair & Grants DSUs
VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) ('Rubicon Organics' or the 'Company'), a licensed producer focused on cultivating and selling organic certified and premium cannabis, reports the voting results from its Annual General and Special Meeting of shareholders (the 'Meeting') held earlier today. A total of 31,130,021 shares were represented in person or by proxy at the Meeting, constituting approximately 46.3% shares represented of the Company's total issued and outstanding Common shares as of the record date, and voted in favour of all matters brought before the Meeting. Results of Annual General and Special Meeting The following matters put forward before shareholders for consideration and approval as set out in Rubicon Organics' management information circular dated June 27th, 2025 (the 'Circular') were approved by the shareholders: A corporate presentation presented at the Meeting is available for viewing on Rubicon Organics' website at . Change to Board Chair The Company also today announced that Len Boggio will step down as Chair of the Board, effective immediately. He will transition to the role of Chair of the Nomination and Governance Committee. The Board has unanimously appointed Doris Bitz, currently serving as independent director since 2023, as the incoming Chair. She brings over 30 years of experience successfully building, scaling and growing manufacturing and CPG businesses in North America. In 2022 she retired from her role as President, Retail of Dessert Holdings, a leading manufacturer of high-quality dessert products, and now serves on multiple boards. Doris has also held executive marketing positions at top-tier CPG companies including PepsiCo Canada and General Mills. Doris holds an HBA and an MBA from the Ivey School of Business at Western University. 'On behalf of the organization, I want to thank Len Boggio for his leadership as Board Chair over the last 2 years in particular his exemplary leadership and commitment to strong corporate governance, and I'm pleased that he will continue to share his extensive governance experience in his role as Chair of the Nomination and Governance Committee,' said Margaret Brodie, Chief Executive Officer. 'I want to welcome Doris Bitz as our new Board Chair. Doris has unique experience in building and scaling businesses and thus is very well-positioned to help elevate our team as we transform and scale in our next phase of growth.' 'I'm honored to step into the role of Chair,' said Doris Bitz. 'I look forward to working closely with the leadership team and Board to scale Rubicon Organics to achieve our vision to be the most trusted, premium global leader in cannabis, building long-term value for shareholders.' Omnibus Equity Incentive Plan The Board of Directors (the 'Board') approved the amendment to the Omnibus Equity Incentive Plan on June 27th, 2025, subject to receipt of shareholder approval at the Meeting. The amended Omnibus Equity Incentive Plan will be administered by the Company's Board, and will permit the grant or issue of Restricted Share Units ('RSU's'), Performance Share Units ('PSU's'), Deferred Share Units ('DSU's'), and options ('Options') to eligible participants. The amended Omnibus Equity Incentive Plan is a fixed plan which provides that the aggregate maximum number of Common Shares that may be issued upon the exercise or settlement of awards granted under the amended Omnibus Equity Incentive Plan is 8,960,180 Common Shares. As set out in the Circular, the Omnibus Equity Incentive Plan replaced the Company's legacy equity incentive plan and legacy DSU plan, and as such, no further grants of stock awards or DSUs will be made under the legacy equity incentive plan or legacy DSU plan. DSU Grant The Company has granted an aggregate of 1,024,576 DSUs pursuant to the Omnibus Equity Incentive Plan to certain independent directors of the Company as compensation for their services in advance for the following 12 months. The DSUs will vest twelve months from the date of grant, and may only be redeemed upon a holder ceasing to be a director of the Company, or as allowed for under the terms of the Omnibus Equity Incentive Plan. ABOUT RUBICON ORGANICS INC. Rubicon Organics is the Canadian leader in certified organic and premium cannabis. With a vertically integrated model and strong national distribution, the company is scaling a house of trusted, high-performing brands including Simply Bare™ Organics, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™. The Company's production base is anchored by its Delta, BC Facility, and is now complemented by the acquisition of our Hope, BC Facility, which will expand production capacity by over 40% and support future growth in both domestic and export markets. With proprietary genetics, award-winning products, and certifications enabling international distribution, Rubicon is positioned at the forefront of the premium cannabis segment. As the Canadian market continues to rationalize and global demand for high-quality cannabis increases, Rubicon's disciplined execution, brand equity, and consumer loyalty set it apart. The Company's focus on premium quality, innovation, and operational execution has driven consistent revenue growth and positive Adjusted EBITDA. Rubicon Organics represents a rare combination of category leadership, operational strength, and long-term growth potential. CONTACT INFORMATION Margaret Brodie Chief Executive Officer Phone: +1 (437) 929-1964 Email: ir@ The TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release. Cautionary Statement Regarding Forward Looking Information This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Rubicon Organics' goal of achieving industry leading profitability are 'forward-looking statements'. Forward-looking information can be identified by the use of words such as 'will' or variations of such word or statements that certain actions, events or results 'will' be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. The forward-looking information in this press release is based on certain assumptions that management considers reasonable under the circumstances, the Company's ability to execute its business strategy, demand for its products in international markets, and other factors beyond the Company's control. These statements are based on current expectations, estimates, and projections about the Company's business and the industry in which it operates. Risks and uncertainties associated with the forward-looking information in this press release include, among others, risks related to regulatory approvals, changes in market conditions, competition, supply chain disruptions, the Company's ability to maintain certification standards, and the successful implementation of its business strategy. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although Rubicon Organics has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although Rubicon Organics has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.
